文献速递白血病

天冬酰胺酶中断对儿童急性淋巴细胞白血病结局的影响

Impact of Asparaginase Discontinuation on Outcome in Childhood Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group.
PubMed 文献 · J Clin Oncol · 2020-04-10

PURPOSE: Asparaginase (ASNase) is an important component of acute lymphoblastic leukemia (ALL) treatment, but is often discontinued because of toxicity. Erwinia chrysanthemi ASNase (Erwinia) substitution was approved in 2011 for allergic reactions.…

要点

  • NCI高危B-ALL未完成全部PEG-ASNase剂量者DFS显著 inferior。
  • 换用Erwinia并完成后续疗程未增加高危患者风险。
  • 慢早期反应标危患者中断ASNase与DFS差相关。

核心结论

  • 天冬酰胺酶剂量中断与较高危患者无病生存期较差相关。
  • 研究结果揭示了Erwinia短缺的严重后果。

研究设计与样本

  • 纳入2004-2011年COG前线试验中1-30.99岁B-ALL患者,AALL0331(NCI标危)5195例和AALL0232(NCI高危)3001例。
  • 维持期界标分析比较接受全部规定PEG-ASNase剂量、换用Erwinia但完成全部剂量、未接受全部ASNase剂量者的DFS。

主要发现

  • PEG-ASNase中断累积发生率在AALL0331为12.2%±4.6%,在AALL0232为25.4%±0.8%。
  • NCI高危患者未接受全部规定ASNase剂量者DFS较差(HR 1.5; 95%CI 1.2-1.9; P=.002)。
  • 换用Erwinia并完成后续疗程者风险未增加(HR 1.1; 95%CI 0.7-1.6; P=.69)。
  • NCI标危患者中断ASNase未显著增加风险(HR 1.2; 95%CI 0.9-1.6; P=.23),但慢早期反应者亚组风险增加(HR 1.7; 95%CI 1.1-2.7; P=.03)。

临床怎么用

  • 对NCI高危B-ALL患者应尽量确保完成全部规定PEG-ASNase剂量。
  • 出现过敏反应时可换用Erwinia并完成后续疗程以降低风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Asparaginase (ASNase) is an important component of acute lymphoblastic leukemia (ALL) treatment, but is often discontinued because of toxicity. Erwinia chrysanthemi ASNase (Erwinia) substitution was approved in 2011 for allergic reactions. Erwinia has, however, been intermittently unavailable because of drug supply issues. The impact of Erwinia substitution or complete ASNase discontinuation is unknown. METHODS: Patients aged 1-30.99 years in frontline Children's Oncology Group trials for B-cell acute lymphoblastic leukemia between 2004 and 2011 (National Cancer Institute [NCI] standard risk [SR]: AALL0331; NCI high risk: AALL0232) were included. The number of prescribed pegaspargase (PEG-ASNase) doses varied by trial and strata. Maintenance therapy did not contain ASNase. Landmark analyses at maintenance compared disease-free survival (DFS) among those receiving all prescribed PEG-ASNase doses versus switching to Erwinia but receiving all doses versus not receiving all ASNase doses. RESULTS: We included 5,195 AALL0331 and 3,001 AALL0232 patients. The cumulative incidence of PEG-ASNase discontinuation was 12.2% ± 4.6% in AALL0331 and 25.4% ± 0.8% in AALL0232. In multivariable analyses, NCI high-risk patients not receiving all prescribed ASNase doses had inferior DFS (hazard ratio [HR], 1.5; 95% CI, 1.2 to 1.9; P = .002) compared with those receiving all prescribed PEG-ASNase doses. Patients with Erwinia substitution who completed subsequent courses were not at increased risk (HR, 1.1; 95% CI, 0.7 to 1.6; P = .69). NCI SR patients who discontinued ASNase were not at elevated risk (HR, 1.2; 95% CI, 0.9 to 1.6; P = .23), except when restricted to those with slow early response, who were prescribed more ASNase because of therapy intensification (HR, 1.7; 95% CI, 1.1 to 2.7; P = .03). CONCLUSION: Discontinuation of ASNase doses is associated with inferior DFS in higher-risk patients. Our results illustrate the severe consequences of Erwinia shortages.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Gupta S, Wang C, Raetz EA, et al. Impact of Asparaginase Discontinuation on Outcome in Childhood Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group. J Clin Oncol. 2020. PMID: 32275469. doi:10.1200/JCO.19.03024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。